<DOC>
	<DOCNO>NCT01223352</DOCNO>
	<brief_summary>The primary objective AC-052-373 ass pharmacokinetic ( PK ) profile two dosing regimen pediatric formulation bosentan child pulmonary arterial hypertension ( PAH ) &lt; 12 year age .</brief_summary>
	<brief_title>Effects Two Dosing Regimens Bosentan Children With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>1 . PAH diagnosis confirm right heart catheterization ( RHC ) : Idiopathic heritable PAH , Associated PAH persist complete repair congenital heart defect ( PAH persistent least 6 month surgery ) PAHCHD associate systemictopulmonary shunt ( global amendment date 09 May 2012 ) 2. WHO functional Class I , II III 3 . Male female ≥ 3 month &lt; 12 year age ( maximum age randomization 11.5 year ) 4 . Body weight ≥ 3.5 kg 5 . Peripheral oxygen saturation ( SpO2 ) ≥ 88 % ( rest , room air ) 6 . Baseline PAHtherapy ( Calcium channel blocker , bosentan , prostanoid , PDE5 inhibitor ) present , stable least 3 month prior screen . During study , background treatment remain stable 7 . Signed informed consent parent legal representative 1 . PAH etiology list 2 . Nonstable disease status 3 . Need plan wean patient intravenous epoprostenol intravenous inhale iloprost 4 . Systolic blood pressure &lt; 80 % low limit normal range 5 . AST and/or ALT value &gt; 1.5 time upper limit normal range . 6 . Moderate severe hepatic impairment , i.e. , ChildPugh Class B C 7 . Hemoglobin and/or hematocrit level &lt; 75 % low limit normal range . 8 . Known intolerance hypersensitivity bosentan excipients dispersible Tracleer tablet 9 . Treatment forbidden medication within 2 week least 5 time halflife prior randomization , whichever long : Glibenclamide ( glyburide ) Cyclosporin A Sirolimus Tacrolimus Fluconazole Rifampicin ( rifampin ) Ritonavir Coadministration CYP2C9 inhibitor ( e.g. , amiodarone , voriconazole ) moderate/strong CYP3A4 inhibitor ( e.g. , amprenavir , erythromycin , ketoconazole , diltiazem , itraconazole ) Endothelin receptor antagonist ( ERAs ) bosentan 10 . Treatment another investigational drug within 1 month prior randomization plan treatment</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>child</keyword>
	<keyword>pediatric</keyword>
	<keyword>bosentan</keyword>
</DOC>